Cameron N E, Cotter M A, Dines K C, Maxfield E K, Carey F, Mirrlees D J
Department of Biomedical Sciences, University of Aberdeen, Scotland, UK.
Diabetologia. 1994 Jul;37(7):651-63. doi: 10.1007/BF00417688.
We examined the effects of aldose reductase inhibition on nerve biochemistry and function, blood flow and endoneurial oxygenation in experimental diabetes mellitus. After 1 month untreated diabetes in rats, treatment with the novel sulphonylnitromethane aldose reductase inhibitor, ZENECA ZD5522, prevented a progressive increase in sciatic nerve resistance to hypoxic conduction failure (p < 0.05). Motor conduction velocity deficits after 4 months untreated diabetes were rapidly returned to normal within 12 days (p < 0.0001) by ZD5522 treatment. Following 2-months untreated diabetes, examination of 1 month ZD5522 treatment dose-response relationships for correction of nerve sorbitol and fructose accumulations and reduction in myo-inositol concentration, sciatic motor and saphenous sensory conduction velocity and sciatic blood flow by laser-Doppler flowmetry revealed poor agreement between nerve function and biochemical indices. In addition, polyol accumulation differed between sciatic and saphenous nerves, the latter showing ten-fold lower sorbitol concentrations. Laser-Doppler blood flow was 60% decreased by untreated diabetes (p < 0.001) and there was a strong correlation between ZD5522-mediated increases in blood flow and conduction velocity (p < 0.0001). Measurement of nutritive endoneurial blood flow by microelectrode polarography and hydrogen clearance showed 44% and 45% deficits for 1 and 2 months untreated diabetes (p < 0.001) that were prevented by ponalrestat and ZD5522 treatments, respectively. In contrast, 2 months myo-inositol treatment from diabetes induction did not prevent reduction in blood flow or sciatic motor conduction velocity. A 37% reduction in endoneurial oxygen tension after 2 months diabetes (p < 0.001) was completely prevented by ZD5522 treatment (p < 0.001). The data show that a very high degree of polyol pathway blockade is necessary to correct nerve functional deficits and that aldose reductase inhibitors have a neurovascular action that does not depend on restoration of nerve myo-inositol.
我们研究了醛糖还原酶抑制对实验性糖尿病大鼠神经生物化学和功能、血流及神经内膜氧合的影响。大鼠未经治疗的糖尿病持续1个月后,用新型磺酰基硝基甲烷醛糖还原酶抑制剂ZENECA ZD5522进行治疗,可防止坐骨神经对缺氧传导衰竭的抵抗力逐渐增加(p<0.05)。未经治疗的糖尿病持续4个月后的运动传导速度缺陷,经ZD5522治疗后在12天内迅速恢复正常(p<0.0001)。在未经治疗的糖尿病持续2个月后,通过激光多普勒血流仪检查ZD5522治疗1个月对神经山梨醇和果糖蓄积的纠正、肌醇浓度的降低、坐骨神经运动和隐神经感觉传导速度以及坐骨神经血流的剂量反应关系,结果显示神经功能与生化指标之间的一致性较差。此外,坐骨神经和隐神经中的多元醇蓄积情况不同,后者的山梨醇浓度低10倍。未经治疗的糖尿病使激光多普勒血流降低60%(p<0.001),并且ZD5522介导的血流增加与传导速度之间存在强相关性(p<0.0001)。通过微电极极谱法和氢清除法测量神经内膜营养性血流,结果显示未经治疗的糖尿病持续1个月和2个月时分别有44%和45%的血流不足(p<0.001),波那司他和ZD5522治疗分别可预防这种不足。相比之下,从糖尿病诱导开始进行2个月的肌醇治疗并不能预防血流减少或坐骨神经运动传导速度降低。糖尿病持续2个月后神经内膜氧张力降低37%(p<0.001),ZD5522治疗可完全预防这种情况(p<0.001)。数据表明,要纠正神经功能缺陷,需要非常高度地阻断多元醇途径,并且醛糖还原酶抑制剂具有不依赖于神经肌醇恢复的神经血管作用。